
|Articles|April 24, 2022
Successful phase 2 trial, Aerie Pharmaceuticals, Inc.’s dry eye candidate advancing to phase 3
Author(s)David Hutton
David Wirta, MD, Medical Director for the Eye Research Foundation, Inc., presents the data of Aerie Pharmaceuticals, Inc.’s novel dry eye product candidate, AR-15512 (0.003%). The successful phase 2 results has propelled the product into phase 3 trials.
Advertisement
Newsletter
Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Ophthalmology Times - Clinical Insights for Eye Specialists
1
FDA clears BVI’s FineVision HP trifocal IOL for the US market
2
Treating myopia today: US-focused treatments, challenges, and global insights
3
US FDA awards Epion Therapeutics EpiSmart cross-linking system Fast Track designation
4
Abeona Therapeutics’ ABO-503 chosen for FDA's Rare Disease Endpoint Advancement Pilot Program
5